Journal of Gastrointestinal Cancer最新文献

{"title":"Correlation between Tomographic and Histopathological Staging in Upfront Resected Gastric Cancer: Enhancing Diagnostic Accuracy in the Era of Perioperative Therapy.","authors":"Kaival Gundavda, Aishvarya Shri Rajasimman, Shraddha Patkar, Renish Chhatrala, Akshay D Baheti, Purvi Haria, Manjushree Kolhe, Manish Bhandare, Vikram Chaudhari, Shailesh V Shrikhande","doi":"10.1007/s12029-025-01245-5","DOIUrl":"https://doi.org/10.1007/s12029-025-01245-5","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the diagnostic accuracy of multidetector contrast-enhanced computerised tomography (MDCT) and to establish a correlation between radiological and histopathological staging in upfront resected localised gastric cancers (GC).</p><p><strong>Methods: </strong>All consecutive patients of resectable, localised GC who underwent upfront elective resection between 2010 and 2022 were included. The initial clinical staging determined during multidisciplinary meetings was compared with the pathological stage obtained after surgery. Subsequently, a retrospective, blinded review was conducted to assign a revised clinical staging, and accuracy was correlated.</p><p><strong>Results: </strong>The analysis of 138 patients revealed varying accuracy of MDCT in determining the T stage (66.9% for T1/T2, 64.6% for T3, and 87.2% for T4) and N stage (60.8% for N0, 63.7% for N1, and 83.2% for N2). The accuracy for stage group ranged from 71 to 78.65%. There was weak agreement observed between the T, N, and overall stage on clinicopathological correlation. However, a blinded radiology review by oncoradiologists resulted in improved accuracy, particularly in T1/T2 disease, and also improved pathological stage correlation.</p><p><strong>Conclusions: </strong>Although MDCT is a valuable initial staging tool for gastric cancer, we found weak agreement between the clinical and the pathological stages in upfront resected gastric cancers. By implementing an expert radiology review and standardising scanning and reporting protocols, we can significantly improve the accuracy and correlation of MDCT with pathology, even for T1/T2 disease. This may help in better selecting patients for upfront surgery versus perioperative chemotherapy, especially in resource-constrained settings.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"123"},"PeriodicalIF":1.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Carcinoma Patients with Advanced Pathological Lymph Node Stage Benefit from Postoperative Radiotherapy: A Retrospective Analysis.","authors":"Guangmin Wan, Quan Wang, Lu Yang, Gang Xu","doi":"10.1007/s12029-025-01219-7","DOIUrl":"https://doi.org/10.1007/s12029-025-01219-7","url":null,"abstract":"<p><strong>Background: </strong>The relationship between regional pathological lymph node status and the benefit of postoperative radiotherapy for gastric cancer remains controversial.</p><p><strong>Methods: </strong>This study included all surgically treated patients diagnosed with positive histology and more than 15 examined lymph nodes between January 2007 and December 2019, using data from the SEER database. Patients who received adjuvant chemotherapy were compared by propensity score matching (PSM), with overall survival (OS) as the primary endpoint and adjuvant radiotherapy (RT) as the only variable. Results of subgroup analyses are presented in a forest plot.</p><p><strong>Results: </strong>We firstly analyzed the number of patients receiving adjuvant RT and observed a gradual decline from 2000 to 2021. A total of 1882 patients were included from 2007 to 2019, with 1301 (69.1%) in the adjuvant RT group and 581 (30.9%) in the no-adjuvant RT group. After PSM, each group included 573 patients. Overall, adjuvant RT did not significantly improve 3-year OS (55.5% vs. 51.1%, p = 0.07). However, in subgroups of patients with pathologic lymph node metastasis (pN3-stage), aged 55-70 years, with tumor size > 89 mm and T3-stage, adjuvant RT was associated with improved outcome (p < 0.05). Further PSM and survival analysis based on different pathological lymph node stages suggested an association between adjuvant RT and outcomes. Improved survival outcomes were observed in pathologically lymph node positive (pN +) and pN3 groups, but no similar effects were seen in pN1 and pN2 groups. For pN0 patients, although no statistical significance was found, the data suggest that adjuvant RT may not provide additional benefit.</p><p><strong>Conclusion: </strong>Adjuvant RT was associated with significantly better prognosis in pN3-stage patients. More researches are needed to further validate the role of adjuvant RT in gastric cancer.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"122"},"PeriodicalIF":1.6,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statin use and Pancreatic Cancer: A Meta-analysis of its Association with Incidence in the General Population and Survival in Patients.","authors":"Jibon Kumar Paul, Mahir Azmal, Omar Faruk Talukder, Ajit Ghosh","doi":"10.1007/s12029-025-01238-4","DOIUrl":"10.1007/s12029-025-01238-4","url":null,"abstract":"<p><strong>Purpose: </strong>Statins have been appearing as a potential anti-cancer agent in numerous studies. The study aimed to unravel the impact of statins in pancreatic cancer in terms of reducing the occurrence (morbidity) and improving survival (mortality).</p><p><strong>Methods: </strong>A comprehensive search of databases was carried out to collect the eligible studies up to July 2024. This meta-analysis evaluates two distinct questions: (1) whether statin use reduces the incidence of pancreatic ductal adenocarcinoma (PDAC) in the general population, and (2) whether statins improve survival among patients diagnosed with PDAC. In total, 39 studies were included in the meta-analysis, comprising 15 case-control studies, 20 cohort studies, three randomized controlled trials, and one non-randomized controlled trial. A generic inverse variance weighted random-effects model was applied to calculate the pooled risk ratio and 95% confidence intervals. Subgroup analyses were performed based on the availability of relevant information.</p><p><strong>Results: </strong>In the total meta-analysis, aggregated results demonstrated a substantial decrease in pancreatic cancer risk in all statin users (RR 0.94; 95% CIs, 0.90-0.97, and p-value = 0.0008). The pooled risk ratio estimate of lipophilic statins was 0.97 (95% CI, 0.87-1.07; P = 0.50; I² = 0.0%). The estimated pooled risk ratios of long-term and short-term statin use were 0.80 (95% CI, 0.69-0.92; P = 0.002; I² = 42%) and 0.86 (95% CI, 0.70-1.06; P = 0.15; I² = 96%), respectively. For long-term and short-term follow-up, the risk ratios were 0.81 (95% CI, 0.70-0.94; P = 0.007; I² = 55%) and 0.96 (95% CI, 0.90-1.02; P = 0.16; I² = 26%), respectively. As for the studies collectively, heterogeneity was tested using the Cochrane chi square test (p-value = = 0.40, I² = 4%). No publication bias was found.</p><p><strong>Conclusion: </strong>The overall outcome of the study indicates that statins might lower the occurrence and increase the survival of PDAC patients.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"121"},"PeriodicalIF":1.6,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Lymph Node Recurrence after Esophagectomy of pT2-3 N0M0 Esophageal Squamous Cell Carcinoma.","authors":"Mei Kang, Yichun Wang, Li Niu","doi":"10.1007/s12029-025-01242-8","DOIUrl":"10.1007/s12029-025-01242-8","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to elucidate the distribution patterns of lymph node recurrence (LNR) in patients with pT2-3N0M0 esophageal squamous cell carcinoma (ESCC) following esophagectomy.</p><p><strong>Methods: </strong>A comprehensive retrospective analysis was conducted on 96 pT2-3N0M0 ESCC patients who experienced postoperative LNR at our institution between January 2010 and August 2019. LNR sites were systematically categorized into cervical, mediastinal, and abdominal regions. Computed tomography imaging was digitally reconstructed to precisely map recurrence locations, followed by rigorous statistical analysis of distribution patterns.</p><p><strong>Results: </strong>The final cohort comprised 96 patients with confirmed LNR, with males constituting 79.2% of the sample and a median age of 61 years. Mediastinal LNR was determined to be the most prevalent (69.8%), followed by cervical (43.8%) and abdominal (33.3%) regions. Cervical recurrences were predominantly identified in lymph node station 104R/L (7.8%), while mediastinal recurrences were predominantly localized to station 106recR (14.5%) and station 105 (10.4%), and abdominal recurrences were concentrated in stations 16a2 (3.6%) and 9 (3.6%). Computerized tomography reconstruction demonstrated a distinctive \"T\"-shaped distribution of LNR in the cervical and upper mediastinal regions in proximity to major vascular structures. The primary tumor location was not found to significantly influence LNR distribution patterns (P > 0.05).</p><p><strong>Conclusions: </strong>LNR in pT2-3N0M0 ESCC predominantly manifests in cervical and upper mediastinal lymph nodes. Administering targeted adjuvant radiotherapy to high-risk patients may be an effective strategy for enhancing therapeutic outcomes. Prospective multicenter studies are warranted to validate these preliminary findings.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"120"},"PeriodicalIF":1.6,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of tumor burden score as a prognostic factor in colorectal cancer liver metastases patients: a retrospective analysis.","authors":"Anton Burlaka, Serhii Zemskov, Volodymyr Bezverkhnyi, Veronika Rozhkova, Vitalii Zvirych, Dupyk Mykhailo, Artem Mykytyuk, Romanna Pavliuk, Volodymyr Skyba","doi":"10.1007/s12029-025-01220-0","DOIUrl":"https://doi.org/10.1007/s12029-025-01220-0","url":null,"abstract":"<p><strong>Purpose: </strong>The assessment of resectability in patients with colorectal cancer (CRC) and multiple liver metastases is primarily a technical decision. However, in cases with unfavourable tumor biology, the clinical benefit of surgery remains limited. Further research is needed to identify additional factors influencing oncological outcomes in these patients to better guide the decision-making process. The aim of this study was to investigate the association of tumor burden score (TBS) and oncological outcome in CRC patients with multiple bilobar metastases.</p><p><strong>Methods: </strong>Five hundred twenty-one consecutive patients who underwent liver resections for CRC liver metastases between January 2002 and January 2024 were identified from the National Cancer Institute (Kyiv, Ukraine) prospective database and analysed retrospectively.</p><p><strong>Results: </strong>The median and 5-year overall survival in cohorts with TBS clusters < 3, ≥ 3-9 and ≥ 9 was 116.2 months, 50.3 months and 29.7 months; and 75.7%, 42.4% and 41.6%, respectively (P < 0.001). TBS index has shown high prognostic specificity and sensitivity for postoperative morbidity with AUC 0.97 on the ROC curve. The multivariate Cox regression model has shown that the TBS clusters have a significant negative impact on overall survival particularly in cohorts with TBS ≥ 3-9 (HR: 2.8, 95% CI: 1.7-4.8, P = 0.0001) and TBS ≥ 9 (HR: 1.4, 95% CI: 1.31-1.46, P = 0.005).</p><p><strong>Conclusion: </strong>In this Ukranian population-based study of patients with resectable CRC liver metastases, high TBS was associated with poorer overall survival.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"119"},"PeriodicalIF":1.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Effect of CEA Cut-Off in Patients with Resectable Colorectal Liver Metastases: A Meta-Analysis and Meta-Regression.","authors":"Antonella Venturino, Giuseppe A Colloca","doi":"10.1007/s12029-025-01244-6","DOIUrl":"10.1007/s12029-025-01244-6","url":null,"abstract":"<p><strong>Background: </strong>Although preoperative carcinoembryonic antigen (CEA) is a variable used in most prognostic scores assessing the outcome of patients with colorectal liver metastases (CRLM) undergoing resection, it is unclear what the optimal cut-off is or in which patient subgroups CEA is most relevant. The purpose of this study is to evaluate the prognostic effect of CEA in resected CRLM patients and to explore in which subgroups CEA is most closely associated with overall survival (OS).</p><p><strong>Methods: </strong>A systematic literature search was performed, selecting studies that evaluated a relationship between preoperative CEA and OS in patients undergoing CRLM radical surgery. A meta-analysis assessed the overall effect size of the relationship on the selected study cohorts, based on CEA cut-off. An evaluation of 21 baseline variables was performed to explore their possible effect on the relationship between CEA and OS.</p><p><strong>Results: </strong>The study confirms a significant negative prognostic effect of increased CEA on OS (HR 1.46, CI 1.30-1.65), but heterogeneity among studies is significant. The effect is consistent for all CEA cut-offs, although the relationship tends to weaken in more recent studies for cut-offs < 10 ng/mL. Meta-regressions also suggest that the prognostic effect may be more pronounced in the elderly. In addition, the effect of CEA ≥ 20 ng/mL on OS appears significantly reduced in the subgroup with mutated RAS carcinoma.</p><p><strong>Conclusions: </strong>For patients with resectable CRLM, the CEA cut-off should be increased to 20 ng/mL, and evaluation in prospective studies of the more pronounced negative prognostic effect of preoperative CEA in the elderly and wild-type RAS CRLM patients is recommended.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"117"},"PeriodicalIF":1.6,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Neoadjuvant Chemoradiotherapy Using Volumetric Modulated Arc Therapy in Locally Advanced Squamous Cell Oesophageal Cancers.","authors":"Sam David, Naveen Mummudi, Anil Tibdewal, Sabita Jiwnani, Karthik V, Kumar Prabhash, Trupti Pai, Jai Prakash Agarwal","doi":"10.1007/s12029-025-01225-9","DOIUrl":"10.1007/s12029-025-01225-9","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemoradiotherapy has been established as the standard of care for locally advanced oesophageal cancers. Most of the evidences on neoadjuvant chemoradiotherapy (NACTRT) comes from the Western world where the predominant histology is adenocarcinoma. This study aimed to study the outcomes of neoadjuvant chemoradiotherapy using CROSS protocol and volumetric modulated arc therapy (VMAT) in locally advanced squamous cell oesophageal cancers.</p><p><strong>Case presentation: </strong>We report a multicentric abdominal inflammatory myofibroblastic tumor in a 6-year-old girl who presented with massive abdominal distention. The sheer size of the mass, coupled with multicentric presentation and absent mobility on clinical examination, would have led to a very morbid surgical exploration. This patient was treated with initial chemotherapy, which led to a dramatic response in both symptoms and size of masses, facilitating a complete surgical resection with negligible postoperative morbidity.</p><p><strong>Methods: </strong>This was a single-institute retrospective analysis utilizing a prospectively collected database where all patients with locally advanced operable oesophageal cancers with squamous histology diagnosed between 2021 and 2022 were screened and included. All patients received neoadjuvant chemoradiotherapy in accordance with the CROSS protocol with all patients receiving radiotherapy using VMAT technique.</p><p><strong>Results: </strong>A total of 102 patients with locally advanced oesophageal cancers with squamous histology were included in the study. The median follow-up for the cohort was 29 months. The 3-year overall survival (OS), disease-free survival (DFS), and local control (LC) were 72%, 59.1%, and 72%, respectively. Pathological complete response was 59.4%. The major Clavien-Dindo classification (≥ class 3) of surgical complications was 32%. Lower incidence of pulmonary (17.7%) and cardiac (5.2%) complications was observed in this cohort.</p><p><strong>Conclusions: </strong>NACTRT using the CROSS protocol enhances the pathological complete response rates and the survival outcomes in locally advanced oesophageal cancers with squamous histology. The utilization of VMAT has been associated with a reduction in postoperative cardiopulmonary toxicities. However, further prospective randomised studies are required to validate the technique's superiority.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"118"},"PeriodicalIF":1.6,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Coprimary KIT Exon 17 and BRAF Mutations in a Small Intestinal GI Stromal Tumor-A Case Report.","authors":"Hashim Ishfaq, Misbah Younus Soomro, Bakhtawar Masood, Rashida Ahmed, Yasmin Abdul Rashid","doi":"10.1007/s12029-025-01236-6","DOIUrl":"https://doi.org/10.1007/s12029-025-01236-6","url":null,"abstract":"<p><strong>Purpose: </strong>Gastrointestinal stromal tumors (GISTs) are rare neoplasms driven by mutations in KIT, PDGFRA, or BRAF. Concomitant KIT/BRAF mutations are exceptionally rare and have historically been regarded as mutually exclusive. We report the first documented instance of a GIST with concurrent KIT exon 17 (D816H) and BRAF exon 15 (V600E) mutations, exploring the implications of these mutations for treatment and prognosis. KIT exon 17 mutations are rare and associated with imatinib resistance, and the literature on concurrent KIT/PDGFRA and BRAF mutations is limited, highlighting the potential of this case to provide valuable insights into the management of similar tumors.</p><p><strong>Methods: </strong>A 70-year-old woman presented with abdominal pain and a 20-year history of intermittent melena. Imaging and histopathological examination confirmed a duodenal GIST. The patient underwent en bloc tumor resection, and next-generation sequencing (NGS) identified co-occurring KIT exon 17 (D816H) and BRAF exon 15 (V600E) mutations. Postoperatively, the patient received adjuvant imatinib therapy for a planned duration of 3 years.</p><p><strong>Results: </strong>The patient tolerated adjuvant imatinib therapy well, experiencing only mild nausea and diarrhea. After 2 years of follow-up, no recurrence of the tumor was detected, and the patient remained in radiological remission with no signs of metastasis or tumor progression.</p><p><strong>Conclusion: </strong>This case demonstrates a favorable outcome in a patient with localized GIST with concomitant KIT exon 17 and BRAF mutations following surgical resection with no evidence of recurrence. These findings underscore the significance of early comprehensive genotyping in GISTs to guide therapy and predict imatinib resistance.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"116"},"PeriodicalIF":1.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Care for Pancreatic Cancer: Harnessing Patient-Derived Organoids.","authors":"L Demyan, M J Weiss","doi":"10.1007/s12029-025-01164-5","DOIUrl":"https://doi.org/10.1007/s12029-025-01164-5","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers. Surgical resection combined with appropriate chemotherapy currently offers the best chance for long-term survival and potential cure. However, effective treatment is hindered by the limited chemotherapy options and the absence of reliable clinical tools to guide chemotherapy selection. Patient-derived organoids (PDOs) have emerged as a promising technology with the potential in precision medicine for PDAC. This review provides an overview of pancreatic organoid genesis, explores the role of PDOs in elucidating PDAC biology within clinically relevant contexts, and concludes by examining current literature on the utility of PDOs as biomarkers for personalized treatment strategies.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"113"},"PeriodicalIF":1.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Significance of Screening Endoscopy at 2-Year Interval for Detecting Pharyngeal and Esophageal Cancer in the Japanese General Population.","authors":"Kazuhiro Kashiwagi, Toshifumi Yoshida, Satoshi Kinoshita, Hiromasa Nakamizo, Rieko Nakamura, Hiromasa Takaishi, Yasushi Iwao, Takanori Kanai","doi":"10.1007/s12029-025-01243-7","DOIUrl":"10.1007/s12029-025-01243-7","url":null,"abstract":"<p><strong>Purpose: </strong>We previously identified examination time and 2-year interval as effective quality indicators for detecting upper gastrointestinal cancer during screening esophagogastroduodenoscopy (EGD). We evaluated the significance of biennial endoscopy in detecting pharyngeal and esophageal cancer.</p><p><strong>Methods: </strong>Individuals who underwent multiple EGD examinations as health checkups at our center between August 2012 and January 2022 were included. Endoscopists were categorized into two groups based on their mean examination time for normal EGD findings, using a threshold of 5 min. The associations between cancer detection rate and these indicators were analyzed using multivariable analyses.</p><p><strong>Results: </strong>Twelve endoscopists performed more than 1000 examinations each, for a total of 28,842 examinations, detecting all (6 pharyngeal and 26 esophageal) cancers. Intervals between endoscopies were classified into three groups: ≤ 1 year (Group 1), 1 to ≤ 2 years (Group 2), and > 2 years (Group 3). This cancer detection rate did not differ significantly between Groups 1 and 2 (p = 0.761) but was significantly higher in Group 3 than in Group 2 (OR = 4.356, 95% CI = 1.161-16.333, p = 0.029). When Groups 1 and 2 were combined (≤ 2 years) and compared with Group 3, an interval of > 2 years was significantly associated with a higher detection rate, including cases not curable by endoscopic resection (OR, 4.710; 95% CI, 1.806-12.282; p = 0.002). Examination time was not associated with the cancer detection rate (p = 0.944).</p><p><strong>Conclusions: </strong>These findings support the significance of biennial endoscopy in detecting pharyngeal and esophageal cancer as well.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"114"},"PeriodicalIF":1.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}